Publications
- When not even four ALK inhibitors are enough2020 | Faculty of Medicine in Pilsen
- Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non-small cell lung cancer treated with erlotinib2020 | Faculty of Medicine in Pilsen
- Effect of clinical parameters on second- and third-line erlotinib treatment of EGFR wild type patients with advanced NSCLC2019 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Second Faculty of Medicine, Central Library of Charles University
- Diagnosing lung cancer in pulmonology centers2018 | First Faculty of Medicine, Second Faculty of Medicine
- Predictive relevance of miR-34a, miR-224 and miR-342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy2018 | Faculty of Medicine in Pilsen
- Immunotherapy in squamous NSCLC - nivolumab clinical data, our experiences with nivolumab treatment2018 | Faculty of Medicine in Pilsen
- Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy2017 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Erlotinib in treatment of NSCLC focusing on patients without EGFR mutation and on combination of erlotinib with bevacizumab2017 | Faculty of Medicine in Pilsen
- Erlotinib in Treatment of NSCLC (Focusing on Patients without EGFR Mutation and on Combination of Erlotinib with Bevacizumab)2017 | Faculty of Medicine in Pilsen
- Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene2016 | Faculty of Medicine in Pilsen, Faculty of Science
Loading network view...